137 related articles for article (PubMed ID: 38733988)
1. Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis.
Sangineto M; Ciarnelli M; Colangelo T; Moola A; Bukke VN; Duda L; Villani R; Romano A; Giandomenico S; Kanwal H; Serviddio G
Cell Rep Med; 2024 May; 5(5):101564. PubMed ID: 38733988
[TBL] [Abstract][Full Text] [Related]
2. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
3. Egr2 drives the differentiation of Ly6C
Iwata A; Maruyama J; Natsuki S; Nishiyama A; Tamura T; Tanaka M; Shichino S; Seki T; Komai T; Okamura T; Fujio K; Tanaka M; Asano K
Commun Biol; 2024 Jun; 7(1):681. PubMed ID: 38831027
[TBL] [Abstract][Full Text] [Related]
4. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
[TBL] [Abstract][Full Text] [Related]
5. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
[TBL] [Abstract][Full Text] [Related]
6. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages.
Mills EL; Kelly B; Logan A; Costa ASH; Varma M; Bryant CE; Tourlomousis P; Däbritz JHM; Gottlieb E; Latorre I; Corr SC; McManus G; Ryan D; Jacobs HT; Szibor M; Xavier RJ; Braun T; Frezza C; Murphy MP; O'Neill LA
Cell; 2016 Oct; 167(2):457-470.e13. PubMed ID: 27667687
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease.
Sangineto M; Ciarnelli M; Cassano T; Radesco A; Moola A; Bukke VN; Romano A; Villani R; Kanwal H; Capitanio N; Duda L; Avolio C; Serviddio G
Redox Biol; 2023 Oct; 66():102846. PubMed ID: 37586250
[TBL] [Abstract][Full Text] [Related]
8. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
9. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
[TBL] [Abstract][Full Text] [Related]
11. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
[TBL] [Abstract][Full Text] [Related]
12. Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease.
Li W; Yu L
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):355-369. PubMed ID: 38833340
[TBL] [Abstract][Full Text] [Related]
13. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
14. Musculoskeletal Progenitor/Stromal Cell-Derived Mitochondria Modulate Cell Differentiation and Therapeutical Function.
Jorgensen C; Khoury M
Front Immunol; 2021; 12():606781. PubMed ID: 33763061
[TBL] [Abstract][Full Text] [Related]
15. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti.
Xie W; Gan J; Zhou X; Tian H; Pan X; Liu W; Li X; Du J; Xu A; Zheng M; Wu F; Li Y; Lin Z
Cell Metab; 2024 Jun; 36(6):1269-1286.e9. PubMed ID: 38838640
[TBL] [Abstract][Full Text] [Related]
16. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.
Miura K; Yang L; van Rooijen N; Ohnishi H; Seki E
Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(11):G1310-21. PubMed ID: 22442158
[TBL] [Abstract][Full Text] [Related]
17. Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
Sarabhai T; Kahl S; Gancheva S; Mastrototaro L; Dewidar B; Pesta D; Ratter-Rieck JM; Bobrov P; Jeruschke K; Esposito I; Schlensak M; Roden M
Metabolism; 2024 Feb; 151():155762. PubMed ID: 38122893
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
[TBL] [Abstract][Full Text] [Related]
19. Studying Macrophages in the Murine Steatotic Liver Using Flow Cytometry and Confocal Microscopy.
Liu Z; Louwe PA; Scott CL
Methods Mol Biol; 2024; 2713():207-230. PubMed ID: 37639126
[TBL] [Abstract][Full Text] [Related]
20. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
